covid-19 outbreak patient Coronavirus

Kamada and Kedrion to develop immunoglobulin product for Covid-19

Reading now: 946
www.pharmaceutical-technology.com

Biopharmaceutical companies Kamada and Kedrion Biopharma have partnered to develop, manufacture and distribute a human plasma-derived polyclonal immunoglobulin (IgG) product for potential Covid-19 treatment.

The partners will leverage Kamada’s IgG platform technology to develop and manufacture the anti-SARS-CoV-2 IgG product. Under the collaboration, Kedrion will collect and provide plasma at its KEDPLASMA centres from recovered Covid-19 patients.

Kamada will carry out product development, manufacturing, clinical development, in collaboration with Kedrion and regulatory filings.

Kedrion Biopharma CEO Paolo Marcucci said: “In light of the current global coronavirus outbreak, Kedrion and Kamada have quickly focused their efforts on

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA